The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Optimizing belantamab mafodotin dosing and ocular toxicity management in myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses practical considerations for the use of belantamab mafodotin in multiple myeloma. Dr Ocio reviews dosing strategies aimed at maintaining efficacy while reducing corneal toxicity, and highlights the importance of early ophthalmologic monitoring and proactive toxicity management in routine clinical practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think what we should do with this belantamab is to start probably with an intense schedule. This is what we have seen here with high doses of initial belantamab. And then also given probably every other cycle. I think this would be good at the beginning. And then once we have achieved the response, then taper down the doses of belantamab and go to every three cycles, which is very convenient for patients...
So I think what we should do with this belantamab is to start probably with an intense schedule. This is what we have seen here with high doses of initial belantamab. And then also given probably every other cycle. I think this would be good at the beginning. And then once we have achieved the response, then taper down the doses of belantamab and go to every three cycles, which is very convenient for patients. And here we keep the response, but we really reduce the side effects, particularly corneal toxicity. Also, you have to be aware of this toxicity with the ophthalmologist. They have to have an ophthalmologist seeing the patients at least at the beginning, in the initial months of treatment. Then probably they can forget about it. It’s not necessary to have this ophthalmologist. But at the beginning it’s important to have that. But we have not to be, well, afraid of this, of this toxicity. This drug is very well tolerated, and this, we are able to manage that quite well with these indications.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
